Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Br J Dermatol ; 141(4): 739-46, 1999 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10583130

RESUMEN

Paraneoplastic pemphigus (PP) is an autoimmune disease, which is frequently associated with non-Hodgkin's lymphoma. Autoantibodies against components of the cytoplasmic plaque of epithelial desmosomes are usually present in the sera and are believed to play a major pathogenic part in acantholysis and suprabasal epidermal blistering. However, another typical histological feature of PP, interface dermatitis with keratinocyte dyskeratosis, is shared with skin diseases that involve epithelial damage mediated by T cells. Here, we present the detailed characterization of the cutaneous T-cell response in a patient with PP and demonstrate a selective epidermal accumulation of activated CD8+ T cells together with an increased local production of interferon-gamma and tumour necrosis factor-alpha, and a strong expression of HLA-DR and ICAM-1 on keratinocytes. Apoptosis was identified as a key mechanism of keratinocyte death, and appeared independent of the FAS/FAS ligand (FAS-L) pathway, as epidermal expression of FAS was not increased compared with normal skin, and FAS-L was undetectable on the protein and mRNA level. Triple therapy with high-dose corticosteroids, cyclophosphamide and intravenous immunoglobulins reduced levels of pemphigus-like autoantibodies and reversed the cutaneous inflammatory reaction leading to long-standing clinical remission. Our findings support the concept of a major contribution of cytotoxic T lymphocytes to the immunopathology of paraneoplastic pemphigus.


Asunto(s)
Erupciones por Medicamentos/etiología , Inmunosupresores/efectos adversos , Linfoma no Hodgkin/tratamiento farmacológico , Pénfigo/etiología , Vidarabina/análogos & derivados , Adulto , Linfocitos T CD8-positivos/patología , Erupciones por Medicamentos/inmunología , Erupciones por Medicamentos/patología , Epidermis/inmunología , Femenino , Antígenos de Histocompatibilidad Clase II/análisis , Humanos , Inmunohistoquímica , Inmunofenotipificación , Etiquetado Corte-Fin in Situ , Molécula 1 de Adhesión Intercelular/análisis , Linfoma no Hodgkin/inmunología , Linfoma no Hodgkin/patología , Pénfigo/inmunología , Pénfigo/patología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Vidarabina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA